ARA-290 (Cibinetide)

Mechanism of Action

ARA-290 (Cibinetide) is a synthetic, non-erythropoietic peptide derived from erythropoietin that works through a distinct receptor pathway to provide tissue-protective and anti-inflammatory effects.

Receptor Binding and Signaling

ARA-290 acts as a specific ligand for the innate repair receptor (IRR), which consists of the erythropoietin receptor (EPOR) paired with the β-common receptor (CD131). This receptor complex is separate from the classical erythropoietin receptor involved in red blood cell production. Evidence shows that ARA-290 "mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke" (PMID: 38488446), confirming its interaction with this pathway.

The compound is described as targeting "the innate repair receptor axis via erythropoietin," suggesting it activates endogenous repair mechanisms through this specialized receptor system (PMID: 36211426).

Anti-Inflammatory Effects

A key mechanism involves reducing inflammatory responses across multiple tissues. Research demonstrates that ARA-290 "reduces cardiac inflammation" and shows protective effects in various inflammatory conditions (PMID: 36741836). The anti-inflammatory action appears to involve modulation of immune cell activity and cytokine production, though the precise downstream signaling cascades require further elucidation.

Tissue Protection Pathways

ARA-290 demonstrates protective effects through multiple mechanisms:

• Apoptosis inhibition: Studies show involvement of "apoptosis and inflammation pathways" in its protective effects against drug-induced organ damage (PMID: 36085231)
• Neural protection: The compound provides "protective effect in peripheral nerve injury" through mechanisms that appear distinct from classical erythropoietin signaling (PMID: 38943972)
• Bone metabolism: Research indicates ARA-290 "inhibits osteoclastogenesis in vitro and increases bone mineral density in mice," suggesting effects on bone remodeling pathways (PMID: 35008482)

Clinical Translation

The mechanism translates to potential therapeutic applications in neurological conditions, metabolic disorders, and inflammatory diseases, as evidenced by clinical trials in diabetic complications, sarcoidosis-related neuropathy, and cognitive function.

Note: While the basic receptor mechanism is established, many downstream signaling details remain under investigation. The evidence base consists primarily of preclinical studies with limited clinical validation.

ARA-290 (Cibinetide) is an erythropoietin-derived peptide that has been investigated across multiple therapeutic areas, with clinical research focused primarily on neurological conditions, metabolic disorders, and inflammatory diseases.

Primary Clinical Areas

Neurological Conditions
Clinical trials have explored ARA-290's potential in several neurological applications. A completed Phase 1/2 study (NCT02070783) examined cognitive and neural effects, while preclinical research demonstrates protective effects in cerebral ischemic stroke through β-common receptor pathways and potential applications in traumatic brain injury and peripheral nerve injury.

Metabolic Disorders
A Phase 2 trial (NCT01933529) investigated ARA-290's effects in prediabetes and type 2 diabetes, though the study status remains unknown. Additionally, a Phase 2 trial for diabetic macular edema was initiated but subsequently terminated (NCT06626971).

Inflammatory and Autoimmune Conditions
A completed Phase 2 study (NCT02039687) evaluated ARA-290's efficacy on corneal nerve fiber density and neuropathic symptoms in sarcoidosis patients, representing the most clinically advanced application with available completion data.

Mechanisms and Therapeutic Targets

Preclinical evidence suggests ARA-290 works through multiple pathways:

• Neuroprotection: Studies indicate protection against cisplatin-induced nephrotoxicity through modulation of apoptosis and inflammation pathways
• Cardiovascular effects: Research shows potential for reducing cardiac inflammation and attenuating age-related declines in heart function
• Bone health: Evidence demonstrates inhibition of osteoclastogenesis and increased bone mineral density in preclinical models
• Renal protection: Studies suggest benefits in hemolytic-uremic syndrome through innate repair receptor mechanisms

Current Clinical Status

The clinical development of ARA-290 appears limited, with only one definitively completed trial in sarcoidosis patients. The termination of the diabetic macular edema trial and unknown status of the diabetes study suggest challenges in clinical translation, despite promising preclinical findings across multiple organ systems.

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Consult healthcare professionals for treatment decisions.

Safety Profile of ARA-290 (Cibinetide)

Limited Safety Data Available

The safety profile of ARA-290 (cibinetide) is not well-established based on currently available evidence. While several clinical trials have been conducted, detailed safety and adverse event data from these studies are not provided in the available literature.

Clinical Trial Status and Safety Implications

The available clinical trial information reveals some concerning patterns:

• At least one Phase 2 trial for diabetic macular edema was terminated (NCT06626971), though the reasons for termination are not specified
• Another trial investigating effects in type 2 diabetes has unknown status (NCT01933529)
• Completed trials include studies in sarcoidosis-related neuropathy and cognitive effects, but safety outcomes from these studies are not detailed in the available evidence

Preclinical Safety Observations

Animal studies suggest ARA-290 may have biological activity across multiple organ systems:

• Cardiovascular effects: Studies show cardiac inflammation reduction and effects on heart function
• Neurological activity: Demonstrated effects on brain tissue and peripheral nerves
• Bone metabolism: Evidence of effects on bone mineral density and osteoclast activity
• Kidney function: Tested in models of nephrotoxicity

However, these studies do not provide comprehensive toxicology or safety data.

Evidence Limitations

The evidence base has significant gaps regarding:

• Specific adverse events and their frequency
• Drug interactions
• Contraindications
• Populations that should avoid the compound
• Long-term safety data
• Maximum tolerated doses

Recommendations

Given the limited safety data available, healthcare providers should exercise extreme caution with ARA-290. Any use should be within the context of properly designed clinical trials with appropriate safety monitoring.

Medical Disclaimer: This information is for educational purposes only and should not be used for medical decision-making. Consult qualified healthcare professionals for medical advice regarding any potential therapeutic use of this compound.

Research Papers and Clinical Trials

ARA-290 (also known as Cibinetide) is an erythropoietin-derived peptide that has been studied across multiple therapeutic areas. The compound works through the β-common receptor pathway rather than traditional erythropoietin receptors, allowing it to provide tissue-protective effects without stimulating red blood cell production.

Neurological Applications

Several studies have investigated ARA-290's neuroprotective properties. A 2024 study published in CNS Neuroscience & Therapeutics demonstrated that ARA290 provides brain tissue protection in mice with cerebral ischemic stroke by acting through the β-common receptor. Additional research from 2025 in Frontiers in Neurology explored the potential of phase-targeted erythropoietin derivatives, including ARA-290, for traumatic brain injury treatment. A separate 2024 review in International Immunopharmacology examined the protective effects of erythropoietin-derived peptides in peripheral nerve injury.

Cardiovascular and Metabolic Effects

Research published in Frontiers in Cardiovascular Medicine (2022) found that this small erythropoietin-derived peptide reduced cardiac inflammation, helped maintain heart function with aging, and extended healthspan in animal models. The anti-inflammatory properties appear to be a key mechanism across multiple therapeutic applications.

Other Applications

Studies have explored ARA-290's effects in kidney disease, bone health, and autoimmune conditions. A 2023 study in Inflammation investigated the compound's protective effects against cisplatin-induced kidney toxicity, focusing on apoptosis and inflammatory pathways. Research published in the International Journal of Molecular Sciences (2021) showed that Cibinetide inhibited bone-destroying cell activity and increased bone mineral density in mice.

Clinical Trials

Four clinical trials have been registered for ARA-290, though results and current status vary:

• A Phase 2 trial examined effects in prediabetes and type 2 diabetes (NCT01933529), with unknown current status
• A Phase 2 study for diabetic macular edema was terminated (NCT06626971)
• A completed Phase 2 trial (NCT02039687) studied the compound's effects on corneal nerve fiber density and neuropathic symptoms in sarcoidosis patients
• A completed Phase 1/2 study (NCT02070783) investigated cognitive and neural effects

The research suggests ARA-290 has broad anti-inflammatory and tissue-protective properties across multiple organ systems, though clinical development appears to have faced challenges based on the terminated trials. The completed studies' results are not detailed in the available evidence.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance.

Protocols

Based on available clinical trial data, ARA-290 (Cibinetide) has been administered using several different dosing regimens, though published protocols are limited:

Reported Dosing Regimens

Subcutaneous Administration:

• Clinical trials have primarily used subcutaneous injection as the route of administration
• Dosing frequencies have ranged from single doses to repeated daily administration over several days to weeks
• Specific dose amounts and exact treatment durations vary significantly between studies

Study Populations:
Published trials have investigated ARA-290 in:

• Sarcoidosis patients (corneal nerve fiber studies)
• Prediabetes and type 2 diabetes patients
• Diabetic macular edema patients
• Healthy volunteers (cognitive/neural effects studies)

Limitations of Available Data

The evidence base for standardized ARA-290 protocols is limited. Most completed clinical trials have not yet published detailed dosing protocols in peer-reviewed literature. The available preclinical studies focus on mechanisms of action rather than clinical dosing guidelines.

Several registered clinical trials investigating ARA-290 have been completed or terminated, but comprehensive protocol data from these studies remains unpublished in the surveyed literature.

Important Disclaimer

This information is for educational purposes only and does not constitute personalized medical advice. ARA-290 dosing protocols should only be determined by qualified healthcare professionals based on individual patient factors, current clinical guidelines, and regulatory approvals. Patients should never attempt to self-administer or determine dosing without proper medical supervision.

The limited published protocol data highlights the need for more comprehensive clinical studies to establish standardized dosing guidelines for ARA-290 across different therapeutic indications.

Outcomes

The evidence for ARA-290 (Cibinetide) outcomes comes primarily from preclinical studies, with limited completed clinical trial data available.

Preclinical Outcomes

Neuroprotection and Brain Injury:

• In cerebral ischemic stroke models, ARA-290 demonstrated brain tissue protection mediated through the β-common receptor pathway
• Studies suggest potential benefits in traumatic brain injury, though specific measurable outcomes are not detailed in the available evidence
• Peripheral nerve injury models showed protective effects, but quantitative results are not specified

Cardiovascular Effects:

• Reduced cardiac inflammation in preclinical models
• Attenuated age-associated declines in heart function
• Extended healthspan in animal studies, though specific metrics are not provided

Kidney Protection:

• Protected against cisplatin-induced nephrotoxicity through modulation of apoptosis and inflammatory pathways
• Showed benefits in hemolytic-uremic syndrome mouse models via targeting the innate repair receptor axis

Bone Health:

• Inhibited osteoclastogenesis in vitro
• Increased bone mineral density in mouse models

Clinical Trial Outcomes

Limited Completed Data:
The evidence shows several clinical trials, but specific measurable outcomes are not detailed in the available literature:

• Sarcoidosis study (NCT02039687): Completed Phase 2 trial examining effects on corneal nerve fiber density and neuropathic symptoms - outcomes not reported in available evidence
• Cognitive effects study (NCT02070783): Completed Phase 1/2 trial - neural and cognitive outcomes not specified in available evidence
• Diabetic macular edema trial (NCT06626971): Terminated, no outcomes available
• Type 2 diabetes/prediabetes study (NCT01933529): Status unknown, outcomes not reported

Evidence Limitations

The strength of evidence is limited by several factors:

• Most data comes from preclinical animal studies
• Specific quantitative outcomes, effect sizes, and statistical significance are not provided in the available evidence
• Clinical trial results are either not reported or trials were terminated/incomplete
• No peer-reviewed publications of clinical trial outcomes are included in the evidence

Disclaimer: This information is for research purposes only and should not be used for medical decision-making. Consult healthcare professionals for medical advice.